Morgan Stanley Virpax Pharmaceuticals, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.24 - $0.82 $36 - $122	150 New	150 $0
Q1 2023 May 15, 2023	SELL	$0.67 - $1.15 $620 - $1,064	-926 Reduced 86.06%	150 $0
Q4 2022 Feb 14, 2023	BUY	$0.62 - $12.0 $6 - $120	10 Added 0.94%	1,076 $0
Q3 2022 Nov 14, 2022	SELL	$1.15 - $11.9 $19,492 - $201,705	-16,950 Reduced 94.08%	1,066 $1,000
Q2 2022 Oct 27, 2022	SELL	$1.22 - $2.25 $73,803 - $136,113	-60,495 Reduced 77.05%	18,016 $30,000
Q2 2022 Aug 15, 2022	SELL	$1.22 - $2.25 $73,803 - $136,113	-60,495 Reduced 77.05%	18,016 $30,000
Q1 2022 Oct 27, 2022	BUY	$1.86 - $3.61 $112,520 - $218,386	60,495 Added 335.78%	78,511 $174,000
Q1 2022 May 13, 2022	BUY	$1.86 - $3.61 $136,931 - $265,764	73,619 Added 1504.89%	78,511 $174,000
Q4 2021 Feb 14, 2022	BUY	$3.19 - $4.89 $8,507 - $13,041	2,667 Added 119.87%	4,892 $16,000
Q3 2021 Nov 15, 2021	BUY	$4.14 - $22.9 $9,211 - $50,952	2,225 New	2,225 $11,000

Ticker VRPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,714,600
Market Cap $7.15M
Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical no...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.